(Q38010777)

26 August 2017

title

Pharmacogenomics of third-generation aromatase inhibitors (English)

1 reference

26 August 2017

1 reference

Abdullah Turkistani

1

1 reference

26 August 2017

Sharon Marsh

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

17 May 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

9

1 reference

26 August 2017

page(s)

1299-1307

1 reference

Organization of the human aromatase p450 (CYP19) gene

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Estrogen production and action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Sources of estrogen and their importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase in the human testis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase in skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase in human bone tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Subcellular Distribution of Aromatase in Human Placenta and Ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Unique distribution of aromatase in the human brain: In vivo studies with PET and [N‐methyl‐11C]vorozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase inhibitors for breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Estrogen-receptor biology: continuing progress and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

The effects of aromatase inhibitors on lipids and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Pharmacogenomics of tamoxifen and aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Human aromatase: gene resequencing and functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Pharmacogenetics of endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

In vitro cytochrome P450-mediated metabolism of exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a huge review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Highly polymorphic human CYP4A11 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

A human minor histocompatibility antigen resulting from differential expression due to a gene deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

A common polymorphism in the 5'-untranslated region of the aromatase gene influences bone mass and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.687721

10.1517/14656566.2012.687721

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference